FDA approves first drug meant to ease Alzheimer's-linked agitation

by Cara MurezA medication to treat agitation in Alzheimer's patients now has approval from the U.S. Food and Drug Administration.The FDA gave supplemental approval to Otsuka Pharmaceutical Company

Updated on: March 30,2024 13

FDA approves first drug meant to ease Alzheimer's-linked agitation

by Cara MurezA medication to treat agitation in Alzheimer's patients now has approval from the U.S. Food and Drug Administration.The FDA gave supplemental approval to Otsuka Pharmaceutical Company

Updated on:March 30,2024 13

FDA panel reviews 1st new Alzheimer's drug in 2 decades

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca

Updated on: March 30,2024 18

FDA panel reviews 1st new Alzheimer's drug in 2 decades

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca

Updated on:March 30,2024 18

Overlapping mechanisms in HIV cognitive disorders and Alzheimer's disease

by Society for NeuroscienceAβ oligomers are elevated in the brains of HIV(+) cases. Paraffin-embedded tissue sections from hippocampus of HIV(-) and HIV(+) individuals were prepared for immunoflu

Updated on: March 30,2024 18

Overlapping mechanisms in HIV cognitive disorders and Alzheimer's disease

by Society for NeuroscienceAβ oligomers are elevated in the brains of HIV(+) cases. Paraffin-embedded tissue sections from hippocampus of HIV(-) and HIV(+) individuals were prepared for immunoflu

Updated on:March 30,2024 18

GluN3A knockout mouse: Alternative model for Alzheimer's neurodegeneration

by Emory UniversityGluN3A (in the diagram, NR3) is an inhibitory subunit within NMDA receptor assemblies, which function as glutamate-gated cation channels. GluN3A is a key regulator of neuronal

Updated on: March 30,2024 20

GluN3A knockout mouse: Alternative model for Alzheimer's neurodegeneration

by Emory UniversityGluN3A (in the diagram, NR3) is an inhibitory subunit within NMDA receptor assemblies, which function as glutamate-gated cation channels. GluN3A is a key regulator of neuronal

Updated on:March 30,2024 20

HBOT showed improvement in Alzheimer's disease

by Louisiana State UniversityCredit: Louisiana State UniversityDr. Paul Harch, Clinical Professor and Director of Hyperbaric Medicine at LSU Health New Orleans School of Medicine, and Dr. Edward

Updated on: March 30,2024 16

HBOT showed improvement in Alzheimer's disease

by Louisiana State UniversityCredit: Louisiana State UniversityDr. Paul Harch, Clinical Professor and Director of Hyperbaric Medicine at LSU Health New Orleans School of Medicine, and Dr. Edward

Updated on:March 30,2024 16

Clinical trial results for lecanemab are a significant step for Alzheimer's, but not a historic breakthrough

by University of New South WalesAmyloid plaques and neurofibrillary tangles occur in the brains of patients with Alzheimer's disease. Credit: Ian JosonPartner companies Eisai and Biogen recen

Updated on: March 30,2024 14

Clinical trial results for lecanemab are a significant step for Alzheimer's, but not a historic breakthrough

by University of New South WalesAmyloid plaques and neurofibrillary tangles occur in the brains of patients with Alzheimer's disease. Credit: Ian JosonPartner companies Eisai and Biogen recen

Updated on:March 30,2024 14

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

by Frederic Calon and Étienne Aumont,The ConversationCredit: AI-generated imageOn Nov. 30, Eisai and Biogen announced theresults of their latest phase 3 clinical trial in Alzheimer's d

Updated on: March 30,2024 11

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

by Frederic Calon and Étienne Aumont,The ConversationCredit: AI-generated imageOn Nov. 30, Eisai and Biogen announced theresults of their latest phase 3 clinical trial in Alzheimer's d

Updated on:March 30,2024 11

Dementia more common in adults with HIV

(HealthDay)—People older than 50 years with HIV are more likely to have dementia than people without HIV, according to a study published online Nov. 24 inAIDS.Jennifer O. Lam, from Kaiser Perman

Updated on: March 30,2024 13

Dementia more common in adults with HIV

(HealthDay)—People older than 50 years with HIV are more likely to have dementia than people without HIV, according to a study published online Nov. 24 inAIDS.Jennifer O. Lam, from Kaiser Perman

Updated on:March 30,2024 13

FDA defends approval of controversial Alzheimer's drug

by Dennis ThompsonThe U.S. Food and Drug Administration has approved the first new drug to treat Alzheimer's disease in nearly two decades, in a controversial decision that left the agency defendi

Updated on: March 30,2024 13

FDA defends approval of controversial Alzheimer's drug

by Dennis ThompsonThe U.S. Food and Drug Administration has approved the first new drug to treat Alzheimer's disease in nearly two decades, in a controversial decision that left the agency defendi

Updated on:March 30,2024 13

First 'gene silencing' drug for Alzheimer's disease shows promise

by University College LondonEffect of MAPTRxon CSF concentrations of p-tau protein and tau/Aβ42. a, The mean percentage change from baseline in p-tau over time according to dose group. b, T

Updated on: March 30,2024 18

First 'gene silencing' drug for Alzheimer's disease shows promise

by University College LondonEffect of MAPTRxon CSF concentrations of p-tau protein and tau/Aβ42. a, The mean percentage change from baseline in p-tau over time according to dose group. b, T

Updated on:March 30,2024 18

HIV drug shown to help protect against build-up of dementia-related proteins in mouse brains

by University of CambridgeGraphical Abstract. Credit:Neuron(2023). DOI: 10.1016/j.neuron.2023.04.006Cambridge scientists have shown how the brain's ability to clear out toxic prot

Updated on: March 30,2024 20

HIV drug shown to help protect against build-up of dementia-related proteins in mouse brains

by University of CambridgeGraphical Abstract. Credit:Neuron(2023). DOI: 10.1016/j.neuron.2023.04.006Cambridge scientists have shown how the brain's ability to clear out toxic prot

Updated on:March 30,2024 20

How COVID-19 might increase risk of memory loss and cognitive decline

by Natalie C. Tronson,The ConversationCredit: CC0 Public DomainOf all frightening ways that the SARS-COV-2 virus affects the body, one of the more insidious is the effect of COVID-19 on the brai

Updated on: March 30,2024 19

How COVID-19 might increase risk of memory loss and cognitive decline

by Natalie C. Tronson,The ConversationCredit: CC0 Public DomainOf all frightening ways that the SARS-COV-2 virus affects the body, one of the more insidious is the effect of COVID-19 on the brai

Updated on:March 30,2024 19